Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Togaviridae
|
| gptkbp:associated_with |
birth defects
|
| gptkbp:belongs_to |
gptkb:Togaviridae
|
| gptkbp:caused_by |
gptkb:rubella
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:complications |
gptkb:psychologist
gptkb:congenital_rubella_syndrome |
| gptkbp:data_usage |
high in susceptible populations
|
| gptkbp:duration |
lifetime after infection
|
| gptkbp:genetic_diversity |
low
|
| gptkbp:healthcare |
gptkb:significant
|
| gptkbp:historical_impact |
major public health success with vaccination
|
| gptkbp:hosts |
gptkb:Person
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rubivirus
|
| gptkbp:incubation_period |
2 to 3 weeks
|
| gptkbp:is_a |
RNA virus
|
| gptkbp:is_compared_to |
varies by region
|
| gptkbp:is_protected_by |
vaccination
|
| gptkbp:is_vulnerable_to |
gptkb:MMR_vaccine
gptkb:Person live attenuated introduced in the 1960s 95% or higher travelers to endemic areas women of childbearing age part of childhood immunization schedule eliminated rubella in many countries |
| gptkbp:occurs_in |
higher in children
|
| gptkbp:public_awareness |
important for vaccination campaigns
|
| gptkbp:replaced_by |
gptkb:government_agency
|
| gptkbp:research_focus |
immune response
epidemiology vaccine development pathogenesis |
| gptkbp:safety_features |
BSL-2 containment recommended
|
| gptkbp:seed_dispersal |
single-stranded RNA
|
| gptkbp:social_responsibility |
gptkb:Chikungunya_virus
PCR global serology Western equine encephalitis virus Sindbis virus Eastern equine encephalitis virus common in unvaccinated populations Ig G antibody test Ig M antibody test |
| gptkbp:symptoms |
fever
rash joint pain |
| gptkbp:transmission |
respiratory droplets
|
| gptkbp:treatment |
supportive care
antiviral drugs immune modulation |
| gptkbp:year_created |
gptkb:1962
|